Synlogic, Inc.
NASDAQ: SYBX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mary Beth Dooley
- Employees
- 1
- Headquarters
- Cambridge, United States
- IPO year
- 2015
- Market cap
- $7.1M
- Website
- https://www.synlogictx.com
Loading SYBX…
Loading profile data…Frequently asked questions about SYBX
What does Synlogic, Inc. (SYBX) do?
Operating as a clinical-stage biopharmaceutical enterprise, Synlogic, Inc. is dedicated to the creation and progression of synthetic biotic therapeutics aimed at addressing metabolic and immunological conditions across the United States. Its robust portfolio features multiple drug candidates: SYNB1618 and SYNB1934, both non-systemically absorbed...
Where does SYBX trade?
Synlogic, Inc. (SYBX) trades on the NASDAQ Global Market.
What sector is SYBX in?
Synlogic, Inc. (SYBX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Synlogic, Inc.?
Mary Beth Dooley is the chief executive officer of Synlogic, Inc. (SYBX).
Where is Synlogic, Inc. headquartered?
Synlogic, Inc. is headquartered in United States.
Does SYBX pay a dividend?
Synlogic, Inc. (SYBX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SYBX go public?
Synlogic, Inc. (SYBX) completed its initial public offering in 2015.